Home > Journals > Biology and research > Magnesium Research > Full text
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Biology and research
Magnesium Research
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
  Printable version
  Version PDF

Re-evaluation of the concept of chronic, latent, magnesium deficiency


Magnesium Research. Volume 24, Number 4, 225-7, December 2011, Commentary to the letter to the Editor

DOI : 10.1684/mrh.2011.0298


Author(s) : Ronald J. Elin, Department of Pathology and Laboratory Medicine, University of Louisville School of Medicine, Louisville, KY 40292, USA.

ARTICLE

mrh.2011.0298

Auteur(s) : Ronald J Elin

Department of Pathology and Laboratory Medicine, University of Louisville School of Medicine, Louisville, KY 40292, USA

Correspondence. Dr. Ronald J. Elin, 627 S. Preston St. #210, Louisville, KY 40202

I appreciate the opportunity to comment on Dr Günther's letter on “Magnesium in bone and the magnesium load test” [1]. He appropriately raises the question of whether the concept of chronic latent magnesium deficiency (CLMD) should be re-evaluated. I coined the term CLMD several years ago to describe individuals who have a small, chronic, negative magnesium (Mg) balance, but whose serum Mg concentration is within the lower part of the reference interval (latent), and from a clinical standpoint are viewed as having normal Mg status [2]. I recently updated the concept of CLMD in this journal [3]. The reference interval for serum Mg concentrations was determined to be 0.75 to 0.955 mmol/L, with a mean concentration of 0.85 mmol/L in a US population of 15,820 individuals between the ages of 18 and 74 years, which were part of the NHANES I Study [4]. I have defined CLMD as a serum Mg concentration of between 0.75 and 0.849 mmol/L (within the reference interval), with a positive Mg load test (MLT) indicating Mg deficiency. I refer to figure 1 in that recent publication, which identifies the three factors leading to a chronic, negative Mg balance; inadequate intake, decreased gastrointestinal absorption, and increased excretion by the kidneys. The most common cause of CLMD is probably inadequate intake based upon the progressive decrease in the Mg content of our diet over the past century due to processing of food and fast foods [5, 6]. Other significant entities causing a chronic, negative Mg balance are diseases such as diabetes mellitus, alcoholism and a growing list of drugs that compromise reabsorption of Mg by the kidney. The status of a small, chronic, negative Mg balance may go on for years, or indeed a lifetime.

As pointed out by Dr Günther, about 50-70% of body Mg is localized in bone and about 30-50% is exchangeable [1]. Studies by Alfrey et al. found an excellent positive correlation (r=0.96) between bone Mg concentration and the serum Mg concentration [7]. This study supports the concept that the exchangeable bone Mg may serve as a reservoir of Mg that acts to maintain a normal serum Mg concentration. However, the equilibrium among most tissue compartments for Mg is reached very slowly, if at all. Studies suggest that the biological half-life of the majority of Mg in the body is between 41 and 181 days [8, 9]. The serum Mg concentration is more labile than the bone Mg content since Mg absorption from the gastrointestinal tract and excretion by the kidneys are continuous processes that act to adjust the serum Mg concentration. For an individual that has a Mg deficiency, the exchangeable bone Mg fraction probably supplements the serum Mg concentration slowly, to achieve a serum Mg concentration within the lower part of the reference interval. It is upon this basis that I have proposed an evidence-based value for the lower limit of the reference interval for the serum Mg concentration for health and normal Mg status, of 0.85 mmol/L [3]. Thus, it seems plausible that if an individual has a small, chronic, negative Mg balance for an extended period of time, there is a reduction in the bone Mg content, and the serum Mg concentration will be in the lower part of the reference interval or even below the lower limit.

The MLT was proposed as a more sensitive test to determine Mg deficiency (total body Mg deficit) than the serum Mg concentration [10]. After all, it is relatively common to have a serum Mg concentration within the reference interval, but yet a total-body Mg deficit. The MLT is a physiological test with many variables and is unique for an individual. The premise for the MLT assumes that bones deficient in Mg would take up intravenously-administered Mg, and thus the excretion of Mg would be reduced over a short time interval, usually 24 hours, which is measured as percentage retention [10]. A further assumption is that the individual has relatively normal renal function. One study has concluded that the MLT “is of limited routine clinical value in older subjects” [11]. Of importance is that two independent studies have found a very significant negative correlation (r =-0.99 and -0.71, p<0.001 respectively, for the two studies) between the MLT and bone Mg concentration [12, 13]. Thus, studies have shown a significant correlation for bone Mg concentration with both the serum Mg concentration (positive) and the MLT (negative).

Dr Günther cites the paper by Cohen et al. [14], and states “it cannot be explained why normomagnesemic osteoporotic patients retained more Mg than controls and why normomagnesemic diabetics, with the same reduction in bone Mg content and the same alteration in bone mineral crystallinity, did not show an abnormal Mg retention” [1]. In this study, the osteoporotic patients have a mean serum Mg concentration of 0.80 mmol/L (compared with the control of 0.875 mmol/L), and an abnormal MLT mean of 38% retention. These osteoporotic patients exhibit CLMD, with a serum Mg concentration within the reference interval (but below my proposed cut-off of 0.85 mmol/L for health) and an abnormal MLT indicating Mg deficiency. On the other hand, the diabetic patients in this study, who have a mean serum Mg concentration of 0.86 mmol/L (greater than my cut-off of 0.85 mmol/L), and a normal MLT with 12% retention, do not have CLMD. I cannot explain the results for women taking an oral contraceptive preparation, but would speculate that it may be related to a drug effect. I agree with Dr Günther that “the localization and state of the nonexchangeable bone Mg are not defined” [1]. The exchangeable Mg in bone probably resides in the hydrated layer adjacent to the apatite core [15]. Dr Günther postulates that in the MLT, the Mg uptake by bone “depends on the total surface of the apatite crystals” [1]. However, it may be that it is the hydrated layer, next to the apatite core, that has the greater responsibility for the results of the MLT. Further, Dr Günther cites a study where the “reductions in bone Mg content exceed the normal exchangeable bone Mg content, indicating an alteration in bone mineral state” [1]. He asks the question as to whether these changes are “caused by Mg deficiency or by changed activity of bone cells?” I think this is a valid question, but it highlights the complexity of the status of bone Mg and how it might be altered in healthy and diseased individuals. Certainly, this area is deserving of further research to understand better bone Mg metabolism. Thus, in my opinion, the examples of the osteoporotic and diabetic patients cited by Dr Günther are consistent with the concept of CLMD. Is there a need to re-evaluate CLMD or do we need a better understanding of bone Mg metabolism?

References

1. Günther T. Magnesium in bone and the magnesium load test (letter). Magnes Res 2011; 24: 223-4.

2. Elin RJ. Laboratory evaluation of chronic latent magnesium deficiency. In: Advances in Magnesium Research. Rayssiguier Y, Mazur A, Durlach J, eds. London: John Libbey 2001: 233-9.

3. Elin R.J. Assessment of magnesium status for diagnosis and therapy. Magnes Res 2010 ; 23 : 1.

4. Lowenstein FW, Stanton M.F. Serum magnesium levels in the United States, 1971-1974. J Am Coll Nutr 1986 ; 5 : 399-414.

5. Marier J.R. Quantitative factors regarding magnesium status in the modern-day world. Magnesium 1982 ; 1 : 3-15.

6. Marier J.R. Magnesium content of the food supply in the modern-day world. Magnesium 1986 ; 5 : 1-8.

7. Alfrey AC, Miller NL, Butkus D. Evaluation of body magnesium stores. J Lab Clin Med 1974 ; 84 : 153-162.

8. Avioli LV, Berman M. Mg28 kinetics in man. J Appl Physiol 1966 ; 21 : 1688-1694.

9. Watson WS, Hilditch TE, Horton PW, et al. Magnesium metabolism in blood and the whole body in man using 28 magnesium. Metabolism 1979; 28: 90-95.

10. Ryzen E, Elbaum N, Singer FR, Rude RK. Parenteral magnesium tolerance testing in the evaluation of magnesium deficiency. Magnesium 1985; 4: 137-47.

11. Martin BJ. The magnesium load test : experience in elderly subjects. Aging Clin Exp Res 1990; 2: 291-6.

12. Cohen L, Laor A. Correlation between bone magnesium concentration and magnesium retention in the intravenous magnesium load test. Magnes Res 1990; 3: 271-4.

13. Rob PM, Dick K, Bley N, Seyfert T, Brinckmann C, Höllreigel V,Friedrich HJ, Dibbelt L, Seelig MS. Can one really measure magnesium deficiency using the short-term magnesium loading test? J Inter Med 1999; 246: 373-8.

14. Cohen L, Laor A, Kitzes R. Bone magnesium, crystallinity index and state of body magnesium in subjects with senile osteoporosis, maturity-onset diabetes and women treated with contraceptive preparations. Magnesium 1983; 2: 70-75.

15. Farlay D, Panczer G, Rey C, Delmas P, Boivin G. Mineral maturity and crystallinity index are distinct characteristics of bone mineral. J Bone Miner Metab 2010; 28: 433-45.


 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]